PHARMAGREEN BIOTECH INC.: 10-Q filed 2022-05-16
What PHARMAGREEN BIOTECH INC. reported in its quarterly report filed 2022-05-16 (fiscal Q2 2022): 23 published measures, 68 facts as tagged in accession 0001477932-22-003449.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-05-16
- Fiscal period
- fiscal Q2 2022
- Accession
- 0001477932-22-003449 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All PHARMAGREEN BIOTECH INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 198,403 | USD | |
| At 2021-09-30 | 373,081 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 2,600,853 | USD | |
| At 2021-09-30 | 2,065,781 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | -2,402,450 | USD | |
| At 2021-12-31 | -1,584,439 | USD | |
| At 2021-09-30 | -1,692,700 | USD | |
| At 2021-03-31 | -1,870,668 | USD | |
| At 2020-12-31 | -1,753,252 | USD | |
| At 2020-09-30 | -2,934,105 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 3,045 | USD | |
| At 2021-09-30 | 25,300 | USD | |
| At 2021-03-31 | 13,515 | USD | |
| At 2020-09-30 | 12,196 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -1,035,741 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -1,017,017 | USD | 182 |
| 2021-10-01 to 2021-12-31 | 18,724 | USD | 92 |
| 2021-01-01 to 2021-03-31 | -3,141,434 | USD | 90 |
| 2020-10-01 to 2021-03-31 | -3,558,544 | USD | 182 |
| 2020-10-01 to 2020-12-31 | -417,110 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | -204,318 | USD | 182 |
| 2020-10-01 to 2021-03-31 | -105,544 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | 200,566 | USD | 182 |
| 2020-10-01 to 2021-03-31 | 156,881 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | -12,716,434 | USD | |
| At 2021-09-30 | -11,699,417 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 394,410,713 | shares | 90 |
| 2021-10-01 to 2022-03-31 | 389,278,687 | shares | 182 |
| 2021-01-01 to 2021-03-31 | 307,043,543 | shares | 90 |
| 2020-10-01 to 2021-03-31 | 231,249,242 | shares | 182 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -458,860 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -662,520 | USD | 182 |
| 2021-01-01 to 2021-03-31 | -136,949 | USD | 90 |
| 2020-10-01 to 2021-03-31 | -238,573 | USD | 182 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 2,557,027 | USD | |
| At 2021-09-30 | 2,026,415 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 622,554 | USD | |
| At 2021-09-30 | 579,851 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 70 | USD | |
| At 2021-09-30 | 290 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 458,860 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 662,520 | USD | 182 |
| 2021-01-01 to 2021-03-31 | 136,949 | USD | 90 |
| 2020-10-01 to 2021-03-31 | 238,573 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 397,221,269 | shares | |
| At 2021-09-30 | 381,171,269 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 9,991,722 | USD | |
| At 2021-09-30 | 9,680,572 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | -28,311 | USD | |
| At 2021-09-30 | -8,378 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -1,053,211 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -1,036,950 | USD | 182 |
| 2021-01-01 to 2021-03-31 | -3,154,134 | USD | 90 |
| 2020-10-01 to 2021-03-31 | -3,613,698 | USD | 182 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 20,904 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 48,117 | USD | 182 |
| 2021-01-01 to 2021-03-31 | 19,248 | USD | 90 |
| 2020-10-01 to 2021-03-31 | 43,660 | USD | 182 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -576,881 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -354,497 | USD | 182 |
| 2021-01-01 to 2021-03-31 | -3,004,485 | USD | 90 |
| 2020-10-01 to 2021-03-31 | -3,319,971 | USD | 182 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | 0 | USD | 182 |
| 2020-10-01 to 2021-03-31 | 0 | USD | 182 |
Income taxes paid, net
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | 0 | USD | 182 |
| 2020-10-01 to 2021-03-31 | 0 | USD | 182 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | -220 | USD | 182 |
| 2020-10-01 to 2021-03-31 | -34 | USD | 182 |
Inspect the source
- Entity
- PHARMAGREEN BIOTECH INC. / CIK 0001435181
- Captured
- SEC response SHA-256
4e00c9aee679589f8868ed439479e9b4ea1a271d889b232e7bdda4b499a910e3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001435181.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))